Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists offer prostate brachytherapy and the patients for whom he still recommends it.
|Articles|May 1, 2007
Oncology NEWS International
- Oncology NEWS International Vol 16 No 5
- Volume 16
- Issue 5
AVEO and Schering-Plough to Develop Anti-HGF Antibody
AVEO and Schering-Plough to Develop Anti-HGF Antibody
Advertisement
CAMBRIDGE, MassachusettsAVEO Pharmaceuticals, Inc. has entered into an exclusive worldwide agreement with Schering-Plough Corporation to develop and commercialize AV-299, a highly potent antagonist of hepatocyte growth factor/scatter factor (HGF/SF). The antibody has shown excellent efficacy in preclinical models of human cancer and is expected to enter clinical trials in early 2008, the companies announced in a press release.
Articles in this issue
over 19 years ago
Escalating Drug Costs Could Provoke Consumer Backlashover 19 years ago
Large Study Casts Doubt on Value of CADover 19 years ago
Cetuximab Does Not Increase Mucositis in H&N Cancerover 19 years ago
2004 Update Shows Continued Lower Breast Ca Incidenceover 19 years ago
Reclast Single-Dose Infusion Approved for Paget's Diseaseover 19 years ago
Fragmin Approved for VTE in Cancer Ptsover 19 years ago
New Phase III Trial of Genasense in Advanced Melanoma Plannedover 19 years ago
Cervical Cancer Vaccines Show Sustained Protectionover 19 years ago
The 'New' Medicare: Passive Payer No More; PQRI Is First StepAdvertisement
Related to this article
Chinmay Jani, MD, explains how air pollution and asbestos contribute to lung cancer deaths beyond tobacco.
Claudine Isaacs, MD, and community oncologists weigh ASCENT-03 and ASCENT-04 data, crossover, and toxicity management with sacituzumab govitecan in TNBC.
The FDA assigned an April 9, 2027, target action date to resubmitted applications for rivoceranib plus camrelizumab in unresectable or metastatic hepatocellular carcinoma.
Adam C. Olson, MD, MSc-GH, discussed letting patients choose between modalities with comparably strong evidence, and the data that shaped his approach.
Data from the phase 3 MANGROVE study support the application for zanubrutinib/rituximab in this mantle cell lymphoma population.
Sunnie Kim, MD, discussed perioperative durvalumab plus FLOT, ctDNA-guided de-escalation, irAE monitoring, and biomarkers in gastroesophageal cancer.
Adam C. Olson, MD, MSc-GH, discussed the infrastructure, training, and shared decision-making behind building a prostate HDR brachytherapy program.
Advertisement
Advertisement
Trending on CancerNetwork
1
Setting Up an HDR Brachytherapy Program Amid a National Decline
2
Zamto-Cel Improves EFS vs R-GemOx in Transplant-Ineligible R/R LBCL
3
CD38-Targeted Immuno-PET Helps Detect Active Multiple Myeloma
4
Biomarker Sequencing, PD-L1 Status, and FLOT Dosing in Gastroesophageal Cancer
5